Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Business Insider North Carolina.
Press releases published on June 6, 2025

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design …

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report …

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to July 9, 2025
New York, NY , June 06, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that on June 5, 2025, it caused to be deposited $0.15 …

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing …

Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th …

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly …

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …

Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology …

NPWR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that NET Power Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz …

OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …

Northann Corp. Issues Statement on Recent Stock Volatility
Fort Lawn, SC, June 06, 2025 (GLOBE NEWSWIRE) -- Northann Corp. (“Northann” or the “Company”) (NYSE American: NCL), a company specializing in 3D printing and manufacturing solutions, today announced that it is not aware of any new material developments or …

NIRI Florida Announces its 2025-2026 Board of Directors
Fort Lauderdale, FL, June 06, 2025 (GLOBE NEWSWIRE) -- The Florida Chapter of NIRI: The Association for Investor Relations is pleased to announce the election of the following individuals to serve on the Board of Directors for the 2025-2026 program year: …

Brighter Days Celebrates Four Years of Delivering Exceptional Support to Individuals with Intellectual Disabilities
Gibsonia, Pennsylvania, June 06, 2025 (GLOBE NEWSWIRE) -- Brighter Days, a provider of in-home and community-based services for individuals with intellectual disabilities, commemorates its fourth anniversary. Founded with a mission to deliver relationship- …

XOVR ETF Adds Anduril, Joining SpaceX to Offer Pre-IPO Access
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- ERShares, the first Crossover ETF that offers retail investors access to Private companies, with SpaceX as its top weight, is ushering in the next generation of investing with a new private equity position in …

Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. According to a federal …

OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), ein globales, im klinischen Stadium tätiges Onkologieunternehmen, das auf die Entwicklung neuartiger Krebstherapien wie Antikörper-Wirkstoff-Konjugate (AWK) (4174. TWO) spezialisiert …

Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™
TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que les conjugués anticorps-médicaments ( …

Steelworkers Humanity Fund donates $20,000 to support wildfire relief efforts in Saskatchewan
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- The Steelworkers Humanity Fund (SHF) is donating $20,000 to support people and communities evacuated due to recent wildfires in Saskatchewan. Following a worsening of weather conditions in Northern Saskatchewan …